Literature DB >> 12795525

Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain.

Israr A Khan1, Richard F Ludueña.   

Abstract

Vinblastine, a highly successful antitumor drug, targets the tubulin molecule. Tubulin, the subunit protein of microtubules, consists of an alpha- and a beta-subunit, both of which consist of isotypes encoded by different genes. We have purified three isotypes of bovine brain tubulin, namely, alpha(beta)II, alpha(beta)III and alpha(beta)IV. Microtubule associated protein-2 (MAP2) and Tau-induced assembly of these isotypes were compared in the presence and absence of vinblastine. MAP2-induced assembly of unfractionated tubulin and all the isotypes except alpha(beta)II tubulin was resistant to 1 microM vinblastine. Vinblastine at low concentrations (< 10 microM) progressively inhibited the assembly of all of the isotypes but the vinblastine concentration required for inhibition of MAP2-induced microtubule assembly was minimal for alpha(beta)II. The tau-induced assembly of unfractionated tubulin and alpha(beta)III were equally sensitive to 1 microM vinblastine whereas alpha(beta)II and alpha(beta)IV were much more sensitive to vinblastine. The microtubules obtained in the presence of tau from unfractionated tubulin, alpha(beta)II and alpha(beta)IV could be easily aggregated by 20 microM vinblastine whereas such as aggregation of microtubules obtained from alpha(beta)III and tau required approximatedly 40 microM vinblastine. Our results suggest that among the tubulin isotypes, alpha(beta)II is the most sensitive to vinblastine in the presence of MAPs while alpha(beta)III is the most resistant and this intrinsic resistance of alpha(beta)III dimers persists in the polymeric form of alpha(beta)III tubulin as well. These results may be relevant to the therapeutic and toxic actions of vinblastine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12795525     DOI: 10.1023/a:1022946305242

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  43 in total

1.  Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly.

Authors:  D W Cleveland; S Y Hwo; M W Kirschner
Journal:  J Mol Biol       Date:  1977-10-25       Impact factor: 5.469

2.  Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.

Authors:  S Ranganathan; D W Dexter; C A Benetatos; A E Chapman; K D Tew; G R Hudes
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin.

Authors:  A Banerjee; M C Roach; P Trcka; R F Ludueña
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

4.  Interaction of estramustine with tubulin isotypes.

Authors:  N Laing; B Dahllöf; B Hartley-Asp; S Ranganathan; K D Tew
Journal:  Biochemistry       Date:  1997-01-28       Impact factor: 3.162

5.  Interaction of vinblastine with calf brain tubulin: multiple equilibria.

Authors:  G C Na; S N Timasheff
Journal:  Biochemistry       Date:  1986-10-07       Impact factor: 3.162

6.  Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

Authors:  C Dumontet; G E Duran; K A Steger; L Beketic-Oreskovic; B I Sikic
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

Review 7.  Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents.

Authors:  R F Luduena; M C Roach
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

Review 8.  Effects of antimitotic agents on tubulin-nucleotide interactions.

Authors:  J J Correia
Journal:  Pharmacol Ther       Date:  1991-11       Impact factor: 12.310

Review 9.  Physical and spectroscopic methods for the evaluation of the interactions of antimitotic agents with tubulin.

Authors:  S N Timasheff; J M Andreu; G C Na
Journal:  Pharmacol Ther       Date:  1991-11       Impact factor: 12.310

10.  Phosphorylation of beta III-tubulin.

Authors:  I A Khan; R F Ludueña
Journal:  Biochemistry       Date:  1996-03-26       Impact factor: 3.162

View more
  13 in total

1.  Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality.

Authors:  Danielle N Margalit; Laura Romberg; Rebecca B Mets; Alan M Hebert; Timothy J Mitchison; Marc W Kirschner; Debabrata RayChaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

2.  The beta isotypes of tubulin in neuronal differentiation.

Authors:  Jiayan Guo; Consuelo Walss-Bass; Richard F Ludueña
Journal:  Cytoskeleton (Hoboken)       Date:  2010-07

3.  Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Authors:  Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee
Journal:  Invest New Drugs       Date:  2015-12-21       Impact factor: 3.850

4.  Interactions of β tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress.

Authors:  Jiayan Guo; Hong Seok Kim; Reto Asmis; Richard F Ludueña
Journal:  Cytoskeleton (Hoboken)       Date:  2018-05-14

5.  Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors:  Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal:  Protoplasma       Date:  2016-12-09       Impact factor: 3.356

6.  Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.

Authors:  Chih-Yuan Tseng; Jonathan Y Mane; Philip Winter; Lorelei Johnson; Torin Huzil; Elzbieta Izbicka; Richard F Luduena; Jack A Tuszynski
Journal:  Mol Cancer       Date:  2010-05-30       Impact factor: 27.401

7.  Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: implications for side effects of general anesthesia.

Authors:  Travis J A Craddock; Marc St George; Holly Freedman; Khaled H Barakat; Sambasivarao Damaraju; Stuart Hameroff; Jack A Tuszynski
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

8.  Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy.

Authors:  Siamak Ravanbakhsh; Melissa Gajewski; Russell Greiner; Jack A Tuszynski
Journal:  Theor Biol Med Model       Date:  2013-05-01       Impact factor: 2.432

9.  Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

Authors:  Marianne S Poruchynsky; Dan L Sackett; Robert W Robey; Yvona Ward; Christina Annunziata; Tito Fojo
Journal:  Cell Cycle       Date:  2008-01-17       Impact factor: 5.173

Review 10.  An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.

Authors:  Amelia L Parker; Wee Siang Teo; Joshua A McCarroll; Maria Kavallaris
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.